GLP-1 users saw a 44% reduction in hospitalizations due to stroke, heart attack and heart failure compared to the control group
doi: 10.3389/fimmu.2023.1148209 Received 19 January 2023 Accepted 26 April 2023 Published 17 May 2023 Volume 14 - 2023 Edited by Christoph Thiemermann, Queen Mary University of London, United Kingdom Reviewed by Marcin Filip Osuchowski, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austria
Evidence & uses: Used for tendinopathy, arthritis pain, muscle strains, and post-injury recovery
However, prolonged exposure to temperatures above 77 degrees Fahrenheit will accelerate degradation
Current or recent use of oral isotretinoin or systemic retinoids (within 6 months)
The investment is intended to upgrade, retrofit and boost capacity at the site for the firms oral GLP-1 products, which are widely used for obesity and diabetes